These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34652918)

  • 21. Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7.
    Zoppi V; Hughes SJ; Maniaci C; Testa A; Gmaschitz T; Wieshofer C; Koegl M; Riching KM; Daniels DL; Spallarossa A; Ciulli A
    J Med Chem; 2019 Jan; 62(2):699-726. PubMed ID: 30540463
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
    Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
    Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate.
    Roy MJ; Winkler S; Hughes SJ; Whitworth C; Galant M; Farnaby W; Rumpel K; Ciulli A
    ACS Chem Biol; 2019 Mar; 14(3):361-368. PubMed ID: 30721025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
    Zhang X; Crowley VM; Wucherpfennig TG; Dix MM; Cravatt BF
    Nat Chem Biol; 2019 Jul; 15(7):737-746. PubMed ID: 31209349
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aptamer-PROTAC Conjugates (APCs) for Tumor-Specific Targeting in Breast Cancer.
    He S; Gao F; Ma J; Ma H; Dong G; Sheng C
    Angew Chem Int Ed Engl; 2021 Oct; 60(43):23299-23305. PubMed ID: 34240523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader.
    Payne NC; Maksoud S; Tannous BA; Mazitschek R
    Cell Chem Biol; 2022 Aug; 29(8):1333-1340.e5. PubMed ID: 35649410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A photoactivatable upconverting nanodevice boosts the lysosomal escape of PROTAC degraders for enhanced combination therapy.
    Zhan J; Li X; Mu Y; Yao H; Zhu JJ; Zhang J
    Biomater Sci; 2024 Jul; 12(14):3686-3699. PubMed ID: 38873991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4.
    Zengerle M; Chan KH; Ciulli A
    ACS Chem Biol; 2015 Aug; 10(8):1770-7. PubMed ID: 26035625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Bhakta S; Blaquiere N; Chen J; Dela Cruz-Chuh J; Gascoigne KE; Hartman SJ; He M; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Liu L; Liu Q; Lu Y; Meng F; Mulvihill MM; O'Donohue A; Rowntree RK; Staben LR; Staben ST; Wai J; Wang J; Wei B; Wilson C; Xin J; Xu Z; Yao H; Zhang D; Zhang H; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2534-2575. PubMed ID: 33596065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
    Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
    Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An updated patent review of BRD4 degraders.
    Ma Z; Zhang C; Bolinger AA; Zhou J
    Expert Opin Ther Pat; 2024 Oct; 34(10):929-951. PubMed ID: 39219068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
    Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
    Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TF-PROTACs Enable Targeted Degradation of Transcription Factors.
    Liu J; Chen H; Kaniskan HÜ; Xie L; Chen X; Jin J; Wei W
    J Am Chem Soc; 2021 Jun; 143(23):8902-8910. PubMed ID: 34100597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
    Ishida T; Ciulli A
    SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
    He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
    J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation.
    Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ
    J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
    Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
    Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment.
    Liang JJ; Xie H; Yang RH; Wang N; Zheng ZJ; Zhou C; Wang YL; Wang ZJ; Liu HM; Shan LH; Ke Y
    Bioorg Med Chem; 2021 Sep; 45():116331. PubMed ID: 34364224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.